Posted by Michael Wonder on 18 Feb 2018
ICER report finds costs of approved CAR-T therapies align with clinical benefit
15 February 2018 - Report will be subject to public deliberation during CTAF meeting on 2 March 2018.
The Institute for Clinical and Economic Review (ICER) today released an evidence report assessing the comparative clinical effectiveness and value of tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead). The report found that both therapies provided improvements in response rates and survival for patients who have exhausted most other treatment options, and that the drugs are priced in alignment with their clinical value.
Both tisangenlecleucel and axicabtagene ciloleucel were evaluated for use in adults with relapsed or refractory B-cell lymphoma. Axicabtagene ciloleucel received approval for this indication in late 2017, while tisagenlecleucel is currently under FDA evaluation. Tisangenlecleucel was also evaluated for paediatric patients with relapsed or refractory B-cell acute lymphoblastic leukaemia, for which it received FDA approval in August 2017.
